Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis.
Edoardo LenciGiulia MarcantogniniValeria CognigniAlessio LupiSilvia RinaldiLuca CantiniIlaria FiordolivaAnna Lisa CarloniMarco RocchiLina ZuccatostaStefano GaspariniRossana BerardiPublished in: Exploration of targeted anti-tumor therapy (2021)
This study underlines the negative prognostic impact of specific metastatic sites, presence of NMD and extrathoracic disease in advanced NSCLC patients treated with immunotherapy. However, TB does not appear to affect the outcome of these patients.